Search

Displaying results 1661 - 1670 of 1723 in total
  1. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug.

  2. Drug

    Sodium bicarbonate

    go.drugbank.com/drugs/DB01390
    ApprovedInvestigational

    Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

    Mixtures: Ora Rinse Liq
  3. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  4. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

  5. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

  6. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    [A258958] In April 2023, the FDA approved the use of omidubicel in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative

  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD.

  8. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577]

  9. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L40548,L40553] On July 13, 2022, nuvaxovid was granted an emergency use authorization by the FDA for the prevention of COVID-19 in adults, which was expanded to include patients ≥12 years of age in August

  10. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.